latest
Clinical Articles

Complement C3 inhibitor (APL-2) meets primary end-point in Phase II clinical trial to treat geographic atrophy

A complement 3 (C3) inhibitor (APL-2) has shown significant results in the experimental treatment of geographic atrophy.   In the Phase II multi-center, randomized, single-masked, sham-controlled study, 246 patients were enrolled across 40 clinical sites in the USA, Australia and New Zealand. Patients received 5 mg APL-2/100 µL, administered via intravitreal injection, either monthly or every […]

Read full story

Systematic review of antioxidant vitamin and mineral use in preventing AMD suggests no benefit when analysed in >76,000 people

A systematic review and meta-analysis to determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD has found no evidence of benefit to their use. The study, conducted by researchers from the London School of Hygiene & Tropical Medicine and the City University of London, published their findings […]

Read full story

Long-term outcomes with aflibercept in diabetic macular edema (DME) – 5 year outcomes reported through extension of previous study

The results of long-term use of aflibercept in patients with macular edema has inidcated that the need for retreatment appears to be substantially reduced in the fourth and fifth years of dosing, following initiation of therapy in a pivotal clinical trial. Researchers based at a number of US retinal clinics reported their findings in the […]

Read full story

Related Clinical News